Group 1: Business Expansion and Strategy - The company has established a subsidiary in Germany to expand overseas business and introduce advanced foreign technologies and products [3] - The company aims to become a one-stop supplier of pharmaceutical consumables, with strategic acquisitions such as controlling Zhejiang Duoling and fully acquiring Suzhou Qingyi to achieve this goal [3][4] - The company is actively responding to the "Belt and Road" initiative by promoting its products to countries along the route [7] Group 2: Production Capacity and Projects - The new production base in Suzhou is nearing completion with an annual capacity of 12,000 tons, combining the original 6,000 tons and an additional 6,000 tons from fundraising projects [3] - There are currently no new production base construction plans, as the focus is on completing existing fundraising projects [6][8] - The company expects to achieve over 50% growth in performance after the completion of fundraising projects, despite a temporary slowdown due to capacity constraints [5] Group 3: Financial Performance and Market Trends - The company has a core product gross margin that is relatively high, with a business model based on sales-driven production [7] - The overall market for children's protective pharmaceutical packaging solutions is not showing significant growth trends [4] - The cold-pressed aluminum packaging material is gaining popularity, with good market promotion conditions [4][6] Group 4: Investor Relations and Market Management - The company is actively managing its market value and will take measures to stabilize stock prices if they decline [4] - The company has a detailed policy to address cost pressures from rising raw material prices [6] - The company plans to utilize capital markets for various operations to achieve its goal of becoming a leader in the industry [6][8]

Group 1: Product Development and Market Position - The company is focusing on developing alternative packaging materials to replace glass bottles, which are high in energy consumption and production costs [2] - Recent advancements in plastic processing technology have allowed the company to create effective packaging solutions that are more efficient and cost-effective than glass [2] - The company has successfully developed several liquid pharmaceutical packaging solutions and aims to extend its offerings further [3] Group 2: Financial Performance and Growth Potential - The company’s subsidiaries are expected to achieve a reasonable profit margin of 12%-15%, indicating significant room for improvement [3] - The pharmaceutical packaging industry has a large market potential, with leading companies in developed countries generating revenues in the billions [4] - The company emphasizes technological innovation and equipment upgrades to improve efficiency and quality, which is crucial for maintaining a profit margin above 10% [5] Group 3: Industry Trends and Competitive Landscape - The domestic pharmaceutical packaging industry is fragmented, with over 1,500 companies, suggesting a future trend towards consolidation [4] - The company recognizes the competitive landscape and aims to enhance its comprehensive competitiveness to advance its business [4] - The company is strategically targeting innovative clients and integrated raw material companies to expand its customer base [6] Group 4: International Market Strategy - The company had plans for local network development overseas, but these have been impacted by the pandemic, particularly in Europe [7] - Southeast Asia remains a promising market for future expansion [7]

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司 投资者关系活动记录表 编号：2020-001 | --- | --- | --- | --- | |----------------|----------------------------|-----------------------------------------------------|---------------------------| | | | | | | | ☑ | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | □ 其他：线上交流活动 | | | | 参与单位名称及 | 兴全基金 -李君 | 交银施罗德基金-徐嘉辰 华泰柏瑞基金-张 | | | 人员姓名 | 弘、彭邦泰 招商基金 | -李世伟 | 天治基金管理有限公司-尹维 | | | | 国 银华基金-王翔、孙昊阳、孙昊天 银河基金-金寿鹏 兴 | | | | 银基金-林德涵 风和亚洲基金 | -李树荣 ...

编号：2020-002 证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|---------------------------------------| | | | | | | ☑ 特定对象调研 □分析师会议 | | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | □ 其他：线上交流活动 | | | | 华安基金 - | 钱坤、张亮 财通基金-杨爱琳 | | 参与单位名称及 | 诺安基金-唐晨 | 富国基金-曾新杰、王园园 | | 人员姓名 | | 中银证券-杨志威、鞠龙 安信证券-吕科佳 | | | 北京泓澄投资-丁力佳 南土资产 | - 范自彬 | | 时间 | 2020 年 7 月 27 日 | 15:30-17:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事长、总经理、董秘——林武辉 | ...

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2020-004 | --- | --- | --- | |----------------|------------------------------|--------------------------| | | | | | | ☑ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | 类别 | □ 现场参观 | | | | □其他：线上交流活动 | | | 参与单位名称及 | 中信证券 李鑫 康达 | | | | 信达证券 汲肖飞 | | | 人员姓名 | 恩宝资产 周翔 | | | 时间 | 2020 年 9 月 16 日 | 15:30-17:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | 员姓名 | 董事长、总经理——林武辉 | | | 投资者关系活动 | 问答环节 | | | --- | --- | |--------------|------------------ ...

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2020-005 | --- | --- | --- | |----------------|------------------------------|------------------------------| | | | | | | ☑ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | □其他：线上交流活动 | | | | 广发基金 李耀柱 | | | 参与单位名称及 | 建信基金 王丽媛 | | | 人员姓名 | 前海开源基金 | 詹世乾 | | 时间 | 2020 年 9 月 24 日 | 15:30-17:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | 员姓名 | | 董事长、总经理、董秘——林武辉 | | 投资者关系活动 | 问答环节 | | | --- | --- | |--------------|---------- ...

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2020-006 | --- | --- | --- | |----------------|-------------------------------|---------------------------------------------| | | | | | | | | | | ☑ 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他：线上交流活动 | | | | 富国基金-李元博 天治基金—梁莉 | | | 参与单位名称及 | | 国海富兰克林基金-刘牧 中欧基金-王建礼、李维 | | | 国信证券 - 肖彬 | 杜杨 安信证券-雷慧华 | | 人员姓名 | 中银国际证券 -李娜 | 聚鸣投资 -王广群 | | | 瀚亚投资-韩依瑾 雷鸣投资 | -胡宏亮 | | 时间 | 2020 年 10 月 20 日 | 15:30-17:00 | | 地点 | 公司会议室 | | | ...

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司 投资者关系活动记录表 编号：2018-06-08 | --- | --- | --- | --- | |--------------|------------------------|------------------------------------|--------------------------------------------------------------| | | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | ■ 现场参观 | | | | | □ | 其他 （请文字说明其他活动内容） | | | 参与单位名称 | | | 浙江证券：王鹏（中小盘组首席分析师）、胡阳艳（中小盘研究员） | | 及人员姓名 | | | | | 时间 | 2018 年 6 月 8 | 日 | | | 地点 | 公司 | | | | 上市公司接待 | | | | | 人员姓名 | ...

Industry Trends - The pharmaceutical packaging industry has undergone significant changes in the past two years due to regulatory adjustments in land supply and industry access, leading to a more centralized market [2] - The demand for high barrier materials is increasing, with domestic usage being less than 1/4 of that in India [5][7] - The market for composite materials in China is approximately ¥20 billion, with domestic quality now comparable to international standards [7] Customer Dynamics - Single customers tend to have a dispersed supplier base due to historical reasons, with stability tests and regulatory approvals causing delays in switching suppliers [2][3] - The company has around 2,000 existing customers, with a focus on building trust to encourage broader product selection [4] Product Development and Market Strategy - The company is actively engaged in R&D, focusing on new materials such as COC/COP for pharmaceutical packaging [4] - The pricing strategy is primarily influenced by competition, with a stable market where quality and stability are prioritized by customers [5] Financial Performance and Projections - The company expects a stable net profit margin, with a focus on maintaining profitability while expanding market share [12] - The company has plans for significant capital investment in new product lines, including cold-formed aluminum and high-barrier composite materials [9][14] Environmental Considerations - The company has made substantial investments in environmental compliance, with initial costs in the tens of millions, but expects to balance operational costs through solvent and energy recovery [7] Future Outlook - The company aims to expand its product categories, particularly in oral and injectable packaging, while also exploring opportunities in high-end food packaging [9][14] - There is a focus on leveraging existing customer relationships to enhance procurement ratios, with some major clients accounting for 70%-80% of purchases [13]

Group 1: Company Performance and Market Position - The company aims to become one of the top five pharmaceutical packaging companies globally, focusing on internal growth and external acquisitions to achieve this goal [4] - In 2020, the company experienced a significant increase in performance, and it is expected to maintain this upward trend in 2021 due to improved management and expanded sales [4] - The company has a healthy financial status with good cash flow, and it is exploring various financing strategies to ensure project advancement [2] Group 2: Investor Relations and Communication - The company is committed to enhancing management and market development to improve performance and maintain transparent communication with investors [4] - The company is currently in the process of a private placement, which has been approved by the board and shareholders, and is awaiting feedback from the exchange [4] - The company has received government support and is actively working on talent acquisition to ensure sustainable development [2] Group 3: Industry Context and Competition - There are 250 listed companies in the pharmaceutical manufacturing sector, but only a few in the pharmaceutical packaging industry, indicating a significant growth potential for the company [1] - The company faces competition from other major domestic pharmaceutical packaging firms, such as Zhongjin Matai and Jiangyin Baobo [4] - The company exports 7.4% of its total sales revenue, collaborating with multinational pharmaceutical companies like Pfizer, AstraZeneca, and Novartis [4] Group 4: Financial Metrics and Projections - The company reported a historical high revenue of 220 million in Q4, although net profit was lower than in Q2 due to varying product profit margins [3] - The total goodwill from acquisitions amounts to 5.4954 million, with 1.0361 million already impaired, indicating a proactive approach to managing goodwill risks [5] - The company anticipates that the second phase of its Nanzhu project will enhance production capacity and market position once completed [2]